Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03850964 · ClinicalTrials.gov registry record · Phase 2
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
A Phase 2 study of Anemia and Hereditary Hemorrhagic Telangiectasia, sponsored by Cure HHT.
- Active
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 11
- Study locations
NCT03850964 is a Phase 2 study of Anemia and Hereditary Hemorrhagic Telangiectasia that is active but no longer recruiting, run by Cure HHT. The registered enrollment target is 70 participants, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (84% lower). The trial reports 11 study locations across 11 states.
The verdict
NCT03850964, a Phase 2 study of Anemia and Hereditary Hemorrhagic Telangiectasia, is active but no longer recruiting, sponsored by Cure HHT.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 11
- Study locations
Study Summary
During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT). Patients will either be provided active drug or a placebo \[sugar - inactive pill\], and be tested for nose bleed severity throughout the trial, including particularly nose bleed duration. Investigators will also test for blood loss, as well as for safety. This study is funded by the US Department of Defense USAMRAA and FDA/OOPD.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG Pazopanib
Study Locations (11)
California
- University of California - Los Angeles - Los Angeles
Colorado
- University of Colorado - Denver
Georgia
- Augusta University - Augusta
Maryland
- John Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University - St Louis
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-05-08 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03850964
The ClinicalTrials.gov registry entry for NCT03850964 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (84% lower). The listed sponsor is Cure HHT, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03850964 reports 11 study locations spanning 11 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT03850964 about?
NCT03850964 is a clinical study titled "Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)". During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT). Patients will either be provided active drug or a placebo \[sugar - inactive pill\], and...
What is the current status of trial NCT03850964?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2023-05-08. Estimated completion is 2026-07.
What conditions does trial NCT03850964 study?
This clinical trial studies the following conditions: Anemia, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nosebleed, HHT.
What interventions are being tested in trial NCT03850964?
The interventions under investigation include: Placebo oral capsule (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT03850964?
This trial is sponsored by Cure HHT, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03850964 being conducted?
This trial has 11 study locations across California, Colorado, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Choline and Iron Deficiency
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.